These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 33376260)

  • 1. Neoadjuvant Therapy in High-Risk Prostate Cancer.
    Ashrafi AN; Yip W; Aron M
    Indian J Urol; 2020; 36(4):251-261. PubMed ID: 33376260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
    Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
    Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
    McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemohormonal therapy followed by robot-assisted and minimum incision endoscopic radical prostatectomy in patients with high-risk prostate cancer: comparison of perioperative and oncological outcomes at single institution.
    Fujita N; Koie T; Hashimoto Y; Narita T; Tobisawa Y; Tanaka T; Noro D; Oikawa M; Hagiwara K; Yoneyama T; Imai A; Yamamoto H; Hatakeyama S; Yoneyama T; Ohyama C
    Int Urol Nephrol; 2018 Nov; 50(11):1999-2005. PubMed ID: 30229466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution.
    Fujita N; Koie T; Ohyama C; Tanaka Y; Soma O; Matsumoto T; Yamamoto H; Imai A; Tobisawa Y; Yoneyama T; Hatakeyama S; Hashimoto Y
    Int J Clin Oncol; 2017 Dec; 22(6):1087-1093. PubMed ID: 28681153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought.
    Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A
    Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study.
    Enokida H; Yamada Y; Tatarano S; Yoshino H; Yonemori M; Sakaguchi T; Nishimura H; Eura R; Nakagawa M
    Jpn J Clin Oncol; 2020 Jan; 50(1):66-72. PubMed ID: 31665352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do androgen-directed therapies improve outcomes in prostate cancer patients undergoing radical prostatectomy? A systematic review and meta-analysis.
    Nayak AL; Flaman AS; Mallick R; Lavallée LT; Fergusson DA; Cagiannos I; Morash C; Breau RH
    Can Urol Assoc J; 2021 Aug; 15(8):269-279. PubMed ID: 33443481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
    Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
    Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
    McClintock TR; von Landenberg N; Cole AP; Lipsitz SR; Gild P; Sun M; Fletcher SA; Roghmann F; Menon M; Nguyen PL; Noldus J; Choueiri TK; Kibel AS; Trinh QD
    Ann Surg Oncol; 2019 Jan; 26(1):297-305. PubMed ID: 30430324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
    Pan J; Chi C; Qian H; Zhu Y; Shao X; Sha J; Xu F; Wang Y; Karnes RJ; Dong B; Xue W
    Urol Oncol; 2019 Dec; 37(12):991-998. PubMed ID: 31466813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
    Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
    Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification of patients with extraprostatic extension and negative lymph nodes at radical prostatectomy: identifying optimal candidates for adjuvant therapy.
    Eisenberg MS; Karnes RJ; Kaushik D; Rangel L; Bergstralh EJ; Boorjian SA
    J Urol; 2013 Nov; 190(5):1735-41. PubMed ID: 23727312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients.
    Sugino F; Nakane K; Kawase M; Ueda S; Tomioka M; Takeuchi Y; Yamada T; Namiki S; Kumada N; Kawase K; Kato D; Takai M; Iinuma K; Tobisawa Y; Ito T; Koie T
    J Robot Surg; 2023 Oct; 17(5):2441-2449. PubMed ID: 37466903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Androgen Receptor Signaling Inhibitors before Radical Prostatectomy for Non-Metastatic Advanced Prostate Cancer: A Systematic Review.
    Yanagisawa T; Rajwa P; Quhal F; Kawada T; Bekku K; Laukhtina E; Deimling MV; Chlosta M; Karakiewicz PI; Kimura T; Shariat SF
    J Pers Med; 2023 Apr; 13(4):. PubMed ID: 37109028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.
    Silberstein JL; Poon SA; Sjoberg DD; Maschino AC; Vickers AJ; Bernie A; Konety BR; Kelly WK; Eastham JA
    BJU Int; 2015 Jul; 116(1):50-6. PubMed ID: 24552276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Strategies Before Radical Prostatectomy for High Risk Prostate Cancer in the Era of New Hormonal Agents.
    Tafuri A; Cerruto MA; Antonelli A
    Curr Drug Targets; 2021; 22(1):68-76. PubMed ID: 32564752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
    Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.
    Zhao X; Xiao YT; Yang Y; Ye Y; Chang Y; Jiang L; Eftekhar M; Ren S; Zhang H
    Cancer Control; 2022; 29():10732748221120462. PubMed ID: 35980734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Degarelix in the Neoadjuvant Setting in Managing Locally Advanced Prostate Cancer.
    Sankaran S; Govindaswamy TG; Dholakia K; Selvaraj N; Kanan D; Tiwari M; Ragavan N
    Cureus; 2023 Jun; 15(6):e40752. PubMed ID: 37363117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.